Yan Gao1,2, Liming Yan1, Yucen Huang1, Fengjiang Liu2, Yao Zhao2, Lin Cao3, Tao Wang1, Qianqian Sun2, Zhenhua Ming4, Lianqi Zhang1, Ji Ge1, Litao Zheng1, Ying Zhang1, Haofeng Wang5,2, Yan Zhu2, Chen Zhu2, Tianyu Hu2, Tian Hua2, Bing Zhang2, Xiuna Yang2, Jun Li2, Haitao Yang2, Zhi‐Jie Liu2, Wenqing Xu2, Luke W. Guddat6, Quan Wang2, Zhiyong Lou1, Zihe Rao1,7,2,3
1Laboratory of Structural Biology, School of Life Sciences and School of Medicine, Tsinghua University, Beijing, China
2Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China
3State Key Laboratory of Medicinal Chemical Biology, Frontiers Science Center for Cell Response, College of Life Sciences, and College of Pharmacy, Nankai University, Tianjin, China.
4State Key Laboratory for Conservation and Utilization of Subtropical Agro-bioresources, College of Life Science and Technology, Guangxi University, Nanning, China
5School of Life Sciences, Tianjin University, Tianjin, China
6School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia
7National Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, CAS, Beijing, China
Tóm tắt
The COVID-19 RNA-synthesizing machine
Many in the scientific community have mobilized to understand the virus that is causing the global coronavirus disease 2019 (COVID-19) pandemic. Gao
et al.
focused on a complex that plays a key role in the replication and transcription cycle of the virus. They used cryo–electron microscopy to determine a 2.9-angstrom-resolution structure of the RNA-dependent RNA polymerase nsp12, which catalyzes the synthesis of viral RNA, in complex with two cofactors, nsp7 and nsp8. nsp12 is a target for nucleotide analog antiviral inhibitors such as remdesivir, and the structure may provide a basis for designing new antiviral therapeutics.
Science
, this issue p.
779
